Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Osaka University spinoff FunPep said on July 5 that it will launch an additional PIII study for its functional peptides-based drug SR-0379 for the treatment of cutaneous ulcers. The new study is scheduled to kick off in 2025. In a…
To read the full story
Related Article
- FunPep’s Functional Peptide Fails in Japan PIII Study for Skin Ulcers
November 25, 2022
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





